Ergomed plc Board Changes (7317C)
October 02 2018 - 9:47AM
UK Regulatory
TIDMERGO
RNS Number : 7317C
Ergomed plc
02 October 2018
PRESS RELEASE
FOR IMMEDIATE RELEASE
Board Changes
Michael Spiteri appointed Non-Executive Director to help drive
digitization strategy
London, UK - 2 October 2018: Ergomed plc (LSE: ERGO) ('Ergomed'
or 'the Company'), a company focused on providing specialised
services to the pharmaceutical industry, today announces two Board
changes with immediate effect.
Michael Spiteri joins the Board as Non-Executive Director.
Michael has nearly 30 years' experience working in information
technology and digital transformation. At Santander's UK Corporate
and Commercial Banking business, he is responsible for digital
strategy, process transformation and digital implementation across
all areas of the business including automation and machine
learning. Prior to Santander, Michael held partner roles at Elixirr
Partners LLP and PricewaterhouseCoopers LLP and senior executive
roles at Accenture and IBM as well as senior management roles at
HCL Axon and Oracle with a focus on financial services clients.
Michael received a BSc in Mechanical Engineering from Paisley
College of Technology.
Andrew Mackie is stepping down as Chief Business Officer and
Board member following the Company's announcement in April to shift
its strategy to focus on services.
Peter George, Chairman of Ergomed, said: "The use of digital
technology to drive both efficiency and accuracy is a strategic
priority for Ergomed, particularly in our pharmacovigilance
business. As a leader in the world of digitization, automation and
AI, Michael's experience and counsel will be invaluable to our
Board as we optimise the Group's operations and drive growth. I
look forward to his input and welcome him to the team.
"I would also like to recognize Andrew's contribution to Ergomed
over the last three years as an executive and for several years
before that as a consultant. We wish him well in his future
endeavours."
Michael Spiteri, Non-Executive Director of Ergomed, said:
"Ergomed is at a key juncture as it embraces and takes advantage of
the opportunities presented by automation and AI. I'm delighted to
be joining the Ergomed Board and I am looking forward to
contributing to the roll-out of its digitization strategy".
Additional Information
Michael William Spiteri (57) has held the following
directorships/partnerships in the past five years:
Current
Behavioural Innovation Ltd: Director
Previous
PriceWaterHouseCoopers LLP: LLP Member
Elixirr Partners LLP: LLP Member
Ergomed confirms that there are no further disclosures to be
made in relation to Rule 17 of paragraph (g) of Schedule Two of the
AIM Rules for Companies in respect of Michael Spiteri's
appointment.
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALLFSVIELFIIT
(END) Dow Jones Newswires
October 02, 2018 09:47 ET (13:47 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024